- The shares of Novavax, Inc. (NASDAQ: NVAX) have received a price target decrease from $317 to $294 by H.C. Wainwright. These are the details.
The shares of Novavax, Inc. (NASDAQ: NVAX) have received a price target decrease from $317 to $294 by H.C. Wainwright. And H.C. Wainwright analyst Vernon Bernardino is reiterating a “Buy” rating on the company shares.
Bernardino cited the company’s first quarter results in the research report. And Bernardino pointed out that with the focused implementation of robust COVID-19 vaccine clinical development programs and the initiation of booster arm studies with NVX-CoV2373, Novavax is “demonstrating long-term vision that ensures a future for widespread distribution and adoption of its COVID-19 vaccines.”
Going forward, Bernardino is expecting the company to remain a solid player in the COVID-19 vaccine landscape. And concerns over a delay in regulatory filings and manufacturing challenges are considered “only temporary setbacks,” according to Bernardino.
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.